Abstract: Crystalline forms of salts of Compound I are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Abstract: The disclosure provides novel solid state forms of Compound I chosen from Compound I Phosphate Salt Hydrate Form A, Compound I free form Monohydrate, Compound I Phosphate Salt Methanol Solvate, and Compound I Phosphate Salt MEK Solvate, compositions comprising the same, and methods of making and using the same, including uses in treating APOL1 mediated disease (such as, e.g., APOL1 mediated kidney disease). Also provided herein are novel solid state forms of Compound II chosen from Compound II Phosphate Salt Hemihydrate Form A, Compound II free form Hemihydrate Form A, and Compound II free form Form C, compositions comprising the same, and methods of making and using the same, including uses in treating APOL1 mediated disease (such as, e.g., APOL1 mediated kidney disease).

Abstract: The disclosure provides novel solid state forms of Compound I selected from Form B, citric acid cocrystal Form A, piperazine cocrystal Form A, urea cocrystal Form A, nicotinamide cocrystal Form A, nicotinamide cocrystal Form B, aspartame cocrystal Form A, glutaric acid cocrystal Form A, L-proline cocrystal Form A, L-proline cocrystal Form B, vanillin cocrystal Form A, and 2-pyridone cocrystal Form A, compositions comprising the same, and methods of using the same, including use in treating APOL1 mediated kidney disease.

Abstract: The present invention relates to pharmaceutical compositions that stabilize and improve the bioavailability of 3-[(1S)- 1-(1-{(S)-(4-chlorophenyl)[3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl]methyl}azetidin-3-yl)-2-fluoro-2-methylpropyl]-5-fluorobenzonitrile. In particular, the present invention relates to pharmaceutical compositions that include 3-[(1S)-1-(1-{(S)-(4-chlorophenyl)[3 -(5-oxo-4,5-dihydro- 1,3,4-oxadiazol-2-yl)phenyl]methyl}azetidin-3-yl)-2-fluoro-2-methylpropyl]-5-fluorobenzonitrile and at least one pharmaceutical acceptable excipient, such as a mono-, di- or triglyceride.

Abstract: N-[1S,2S]-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-trifluoromethyl]pyridine-2-yl}oxy}propanamide (Compound I) has surprisingly improved solubility and bioavailability in a lipophilic vehicle comprising a pharmaceutically acceptable digestible oil, a surfactant, or a cosolvent, or a mixture of any two or more thereof. In one embodiment of the present invention are self-emulsifying or self-microemulsifying composition comprising 1) Compound I; 2) a surfactant having an HLB of 1 to 8; and 3) a surfactant having an HLB of over 8 to 20; and optionally, 4) a digestible oil and/or cosolvent and/or antioxidant or preservative.

Abstract: The present invention relates to particular radiolabeled Cannabinoid-1 (CB1) receptor modulators, and methods of using these modulators for labeling and diagnostic imaging of Cannabinoid-1 receptors in mammals, particularly humans. In addition, intermediates useful for the synthesis of the radiolabeled Cannabinoid-1 receptor modulators are also disclosed, as well as the processes for synthesizing the radiolabeled Cannabinoid-1 receptor modulators. Still further, formulations of the radiolabeled Cannabinoid-1 receptor compounds are described.